logo
A GP doling out football tickets? It may sound daft, but ‘social prescribing' could make a difference in the NHS

A GP doling out football tickets? It may sound daft, but ‘social prescribing' could make a difference in the NHS

The Guardian29-07-2025
A new NHS pilot in Gloucestershire gives 12 GP practices the ability to prescribe Forest Green Rovers football tickets to patients with mild to moderate depression. It's part of a movement towards replacing a purely medical model – think: what antidepressants should we prescribe? – to a social and community model of care. Initiatives like this are easy to mock for being insufficient to address the huge strains faced by the NHS. And, for better or worse, may lead to an increase in people seeking care for depression in the hope of free football tickets. But this sort of thing has been supported by the health secretary, Wes Streeting, as part of his efforts to change the NHS from a sickness treatment system to a preventive health service.
The rationale is that GPs are overwhelmed, with patients showing up with issues such as back and neck pain, depression and anxiety, or just overall fatigue, headaches and feeling unwell. The medical approach is to prescribe medications – in fact, the NHS in 2023-24 prescribed more than 89m antidepressant courses (for an estimated 8.7 million identified patients who received at least one drug) – at great cost to both individuals, given the side-effects, and to the budget of the health service.
And yes, there is a strong pharmaceutical lobby pushing magic bullets and drugs on to individuals. Can't sleep? Take a melatonin pill. Anxious? Take Xanax. Obese? Try a GLP-1 agonist such as Ozempic or Wegovy. In pain? How about oxycodone (which carries the risk of opioid dependency). Perhaps we have been overmedicalising how we treat common conditions that people go to see a GP about. Which is where the idea of social prescribing comes in – that is, referring patients not for specialised care or medication, but instead linking illness to community resources found in exercise, nature, community, music – or even football matches.
There's no need to hammer on about prevention – I think it's universally agreed that prevention is better than cure. But it's easier said than done (as I've written about extensively). To develop the implementation of schemes, pilots have been launched with promising results. NHS England refers to a 2017 University of Westminster evidence summary which estimated 28% fewer GP consultations and 24% fewer A&E visits for people in a social-prescribing scheme. This is not just in the UK, but part of a growing global policy approach whether in Denmark, Canada or Malaysia.
For example, the Danish health authority funded a pilot scheme called Kulturvitaminer (culture vitamins), which offered those unemployed or on state sick leave and suffering from stress, anxiety or depression, support over 10 weeks to be part of cultural activities such as a singing group, a guided reading club, or a drama class. Data from the trial found that participants were happier, more motivated and felt better physically.
Yet, we can't just talk about joining a new walking group, cooking club or art class without considering the larger stresses of modern life that often cause these chronic health issues. Inequality has increased in the UK – driven by Brexit, the pandemic and record inflation: just look at the simultaneously growing numbers of billionaires and food banks. Housing is increasingly unaffordable, while salaries stagnate. Life is indeed harder, especially for young people unsure about their economic futures and quality of life.
In almost every health metric, the poorest communities are also the sickest. As the divide grows between the top 1% and the rest of the population, an increasing number of people are pushed into hardship, including many in traditionally middle-class occupations such as teaching and nursing, whose incomes do not support the same standard of living as that of the previous generation working in the same jobs. Prevention is also about ensuring stable and affordable housing, a living wage and social support. The biggest health challenges aren't medical, but social, economic and political.
At least social prescribing is a step forward in recognising that health issues are often the result of underlying isolation, precarity and stress, and in offering a route into individuals feeling more integrated and supported. In giving free football tickets, perhaps it's giving a moment of joy and support to someone – who a GP has identified as feeling isolated, disconnected and depressed – who otherwise might not have been able to afford or even dream of that kind of experience. The football ticket pilot won't fix the NHS or Britain's underlying economic troubles, but it's a step in the right direction of seeing health as something built in communities and not in hospitals or clinics.
Prof Devi Sridhar is chair of global public health at the University of Edinburgh
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Urgent warning about the rise of a deadly disease spreading in Australia - and it can cause people to go blind
Urgent warning about the rise of a deadly disease spreading in Australia - and it can cause people to go blind

Daily Mail​

time18 minutes ago

  • Daily Mail​

Urgent warning about the rise of a deadly disease spreading in Australia - and it can cause people to go blind

A deadly Victorian-era STI that was nearly eradicated in the early 2000s is making a comeback, infecting a rising number of women in major Australian cities across the country. Federal government figures show syphilis among women of childbearing age increased by five per cent in one year and is up 20 per cent over a five-year period. The bacterial infection, once rampant in the 1800s, is primarily transmitted through oral, vaginal, and anal sex and can also spread during pregnancy. Often dubbed a silent disease, syphilis may show no symptoms for years, and when symptoms do appear, they typically begin 10 to 90 days after infection. It is treatable with antibiotics. Untreated cases can eventually lead to serious complications, including blindness, paralysis, organ damage, dementia, and death. The Royal Australian College of GPs said last year 8,928 cases of syphilis were reported in Australia, compared to 3,881 a decade ago, and 1,962 cases in 2004. RACGP sexual health expert Sara Whitburn said the geography of syphilis infections is changing, shifting from remote and rural northern Australia to large cities, with NSW and Victoria recording the highest percentage of infections in 2025. Dr Whitburn said she was seeing more women presenting at GPs with symptoms of an STD but were often shocked when they tested positive for syphilis. 'People might be aware of chlamydia, but still are often quite shocked to have chlamydia, even though it's very, very common,' she said. 'And then syphilis, I think people think of this as, you know, oh, isn't that a Victorian era disease seen in literature and movies.' Dr Whitburn added that the widespread use of PrEP (Pre-Exposure Prophylaxis) among gay and bisexual men to prevent HIV infection had partly led to an increase in syphilis infections, as it was linked to a decline in condom use in that group. 'When there is people who cross from those populations to non-Indigenous women, women who might have partners who also identify as gay bisexual men, we start to see syphilis in those populations,' she said. 'With COVID and the lockdown, people have perhaps forgotten a little bit around negotiating and communicating around safer sex.' Dr Whitburn partly attributed the rise in syphilis among women of childbearing age to better screening, given pregnant women are particularly at risk, with the infection known to cause stillbirths and miscarriages, as babies can contract the disease while in the womb. 'We're really actively looking to screen for syphilis in that age group because we know that it can actually cause congenital syphilis, which can be life threatening, or can cause quite significant illnesses.' Curtin University epidemiologist Dr Jennifer Dunne told newsGP new research found congenital syphilis triples the risk of preterm birth. Left untreated, congenital syphilis can cause blindness, deafness, intellectual disabilities, and skeletal deformities in babies - and can be fatal. Of 100 cases of congenital syphilis reported between 2016 and 2024, there were 33 deaths recorded. According to the National Syphilis Surveillance quarterly report, rising syphilis cases among women of reproductive age have coincided with a record number of diagnoses of congenital syphilis in 2023, the highest since 1995, and the highest number of related infant deaths ever recorded in a single year. Worryingly, up to a quarter of women were unaware they had syphilis until they were tested during pregnancy. Dr Dunne said the findings reinforce the need for changes in STI testing during pregnancy amid the 'potentially devastating outcomes' for parents. 'Current STI screenings happen early in pregnancy, but we need additional checks later in pregnancy, especially in high-risk areas,' she said. Syphilis was almost entirely eradicated in Australia by the early 2000s, but cases have exploded following an outbreak in north-west Queensland in 2011. Since then, the disease has spread nationwide. In response to rising rates, the Australian Government launched the National Syphilis and Surveillance Monitoring Plan in 2021, with one key goal: reducing syphilis incidence among women of reproductive age. Suburbs within Sydney's affluent inner city, such as Newtown, Surry Hills, and Zetland, have seen a spike in syphilis cases, according to the latest quarterly report. Rising syphilis infections is a trend being seen across the globe, with one in every 1,000 people in parts of England testing positive, as officials warn cases have reached the highest level since 1948. The World Health Organisation estimates 8 million adults between 15 and 49 years old acquired syphilis in 2022 alone. It has a global initiative for the elimination of congenital syphilis. There is no vaccine against syphilis.

Patients to be fast-tracked on to new head and neck cancer vaccine trial
Patients to be fast-tracked on to new head and neck cancer vaccine trial

South Wales Argus

timean hour ago

  • South Wales Argus

Patients to be fast-tracked on to new head and neck cancer vaccine trial

The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancer, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50%. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. She added: 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'

Patients to be fast-tracked on to new head and neck cancer vaccine trial
Patients to be fast-tracked on to new head and neck cancer vaccine trial

Leader Live

timean hour ago

  • Leader Live

Patients to be fast-tracked on to new head and neck cancer vaccine trial

The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancer, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50%. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. She added: 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store